Eisai Co., Ltd. is conducting a Phase 3 clinical trial comparing the efficacy and safety of a higher dose (23 mg) of Donepezil Hydrochloride to the standard 10 mg dose in Japanese patients with severe Alzheimer's disease. The market for Alzheimer's treatments is significant, with increasing prevalence in aging populations. The trial's completion in March 2015 positions Eisai to potentially expand its market share in the cholinesterase inhibitor segment, particularly in Japan, where the demand for effective Alzheimer's therapies is high. Competitive implications include the need to differentiate from existing treatments and address the limitations of current therapies, which may enhance Eisai's strategic positioning in the neurodegenerative disease market.